Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol

BACKGROUND: Two main therapies, pazopanib and sunitinib, are used in the first-line setting for metastatic renal cell carcinoma (mRCC). These two tyrosine kinase inhibitors (TKI) are equally effective in terms of survival; however, they frequently induce adverse events. In this setting, Health-Relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouillet, Guillaume, Fritzsch, Joëlle, Paget-Bailly, Sophie, Pozet, Astrid, Es-Saad, Ikram, Meurisse, Aurelia, Vernerey, Dewi, Mouyabi, Kristina, Berthod, Diane, Bonnetain, Franck, Anota, Amélie, Thiery-Vuillemin, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360763/
https://www.ncbi.nlm.nih.gov/pubmed/30717745
http://dx.doi.org/10.1186/s12955-019-1085-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360763/
https://www.ncbi.nlm.nih.gov/pubmed/30717745
http://dx.doi.org/10.1186/s12955-019-1085-1

Ejemplares similares